Andrew Callos
EVP, Chief Commercial Officer. Files against CYTK. Everything below is filed with the SEC within two business days of the trade. Filed as Callos Andrew.
Every reported line
Purchases, sales, grants, option exercises and shares withheld for tax.
| Company | Action | Value |
|---|---|---|
| CYTKCytokinetics Inc2026-08-31 | Option exercise10b5-1 plan | $232.6K |
| CYTKCytokinetics Inc2026-08-31 | Sale10b5-1 plan | $702.4K |
| CYTKCytokinetics Inc2026-08-31 | Option exercisederivative10b5-1 plan | — |
| CYTKCytokinetics Inc2026-07-30 | Option exercise10b5-1 plan | $325.6K |
| CYTKCytokinetics Inc2026-07-30 | Sale10b5-1 plan | $1.1M |
| CYTKCytokinetics Inc2026-07-30 | Option exercisederivative10b5-1 plan | — |
| CYTKCytokinetics Inc2026-07-01 | Option exercise10b5-1 plan | $348.9K |
| CYTKCytokinetics Inc2026-07-01 | Sale10b5-1 plan | $1.3M |
| CYTKCytokinetics Inc2026-07-01 | Option exercisederivative10b5-1 plan | — |
Source: SEC Form 4 and Form 144 filings, via EDGAR. Form 144 carries no filer identifier, so those notices are matched to this page by name alone. Value is shares times the reported price, and is blank where the filing priced the transaction at zero — a grant costs its recipient nothing. Insiders sell for reasons that have nothing to do with the company, which is why a sale is not read as a signal on its own.
Follow Andrew Callos by email
Andrew Callos's new Form 4 trades, with the rest of the week's filings. One email a week, free.
Unsubscribe with one click from any email.